close
  • Approved Use: Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.
Talking to a doctor who
treats migraine
Talking to a doctor who
treats migraine

Here are some resources to help you find a doctor and start preparing for your next migraine conversation.

Connect with a doctor online

Ask your doctor if they offer visits. There are also services that directly offer online appointments with doctors who treat migraine like the one(s) below.

As with any appointment, it’s important to remember that speaking with a doctor through a telehealth platform does not guarantee a prescription of Aimovig or any other medication.

Prepare for your appointment by using our personalized doctor discussion guide.
Search for a doctor at American Migraine Foundation

Find a doctor near you

Search for a neurologist or primary care doctor by ZIP code. Either can talk to you—in person or online—to see if Aimovig may be right for you.

Try our personalized doctor discussion guide

Our doctor discussion guide could help share the impact of migraine with your doctor.

Don't have a doctor? Here are some resources to help find one.

    *Notice of Third Party Site:

  1. Access to americanmigrainefoundation.org and/or Nurx.com is not intended to provide medical advice or a referral to a particular physician;
  2. Patients should discuss with their physician their experience with the patient’s medical condition and should then determine if the physician is qualified to perform the procedure;
  3. Patients should discuss the risks and benefits of any treatment with their physician;
  4. americanmigrainefoundation.org and/or Nurx.com are independent entities and not affiliated with, or agents of, Amgen Inc.
  5. Amgen Inc. has not entered into any agreement with any doctor affiliated with americanmigrainefoundation.org or Nurx.com to render any treatment or care to any patient, and has not evaluated the credentials, experience or expertise of any physician affiliated with, or referred through, americanmigrainefoundation.org and/or Nurx.com. Reliance on any information provided by accessing americanmigrainefoundation.org and/or Nurx.com is solely at patients' own risk.
  6. COMPANY DOES NOT ENDORSE, NOR DOES IT CONTROL OR TAKE RESPONSIBILITY FOR THE CONTENT OR INFORMATION OR SERVICES ACCESSED THROUGH AMERICANMIGRAINEFOUNDATION.ORG AND/OR NURX.COM; AMGEN INC. MAKES NO EXPRESS, IMPLIED OR STATUTORY WARRANTIES OR REPRESENTATIONS (INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE) FOR THE AMERICANMIGRAINEFOUNDATION.ORG AND/OR NURX.COM. TO THE MAXIMUM EXTENT PERMITTED BY LAW, AMGEN INC. AND ITS AFFILIATES ARE NOT RESPONSIBLE FOR AND EXPRESSLY DISCLAIM ALL LIABILITY, INCLUDING WITHOUT LIMITATION, FOR DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, AND SPECIAL OR OTHER DAMAGES ARISING FROM OR RELATED TO THE USE OF ANY SERVICES OFFERED BY AMERICANMIGRAINEFOUNDATION.ORG AND/OR NURX.COM. BY ACCESSING AMERICANMIGRAINEFOUNDATION.ORG AND/OR NURX.COM, YOU AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW THAT YOU WILL HOLD AMGEN INC. AND ITS AFFILIATES HARMLESS FROM ANY AND ALL CLAIMS ARISING FROM OR IN CONNECTION WITH ANY ACT OR OMISSION OF AMERICANMIGRAINEFOUNDATION.ORG AND/OR NURX.COM.

Contact us here

1-833-AIMOVIG (1-833-246-6844)

8AM–9PM ET, Mon–Fri

+ +

Important Safety Information

Who should not use Aimovig®?
Do not use Aimovig if you are allergic to erenumab-aooe or any ingredients in

Who should not use Aimovig? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are allergic to rubber or latex, pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.

 

Important Safety Information

Who should not use Aimovig®? Do not use Aimovig® if you are allergic to erenumab-aooe or any ingredients in Aimovig®. Before starting Aimovig®, tell your healthcare provider (HCP) about all your medical conditions, including if you are allergic to rubber or latex, pregnant or plan to become pregnant, breastfeeding or plan to breastfeed. Tell your HCP about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements. What are possible side effects of Aimovig®? Aimovig® may cause serious side effects, including:
  • Allergic reactions. Allergic reactions, including rash or swelling can happen after receiving Aimovig®. This can happen within hours to days after using Aimovig®. Call your HCP or get emergency medical help right away if you have any of the following symptoms of an allergic reaction: swelling of the face, mouth, tongue or throat, or trouble breathing.
  • Constipation with serious complications. Severe constipation can happen after receiving Aimovig®. In some cases people have been hospitalized or needed surgery. Contact your HCP if you have severe constipation.
  • High blood pressure. High blood pressure or worsening of high blood pressure can happen after receiving Aimovig®. Contact your healthcare provider if you have an increase in blood pressure.
The most common side effects of Aimovig® are pain, redness, or swelling at the injection site and constipation. These are not all of the possible side effects of Aimovig®. Call your HCP for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Click here for the full Prescribing Information and Patient Product Information.

Approved Use

Aimovig® is a prescription medicine used for the preventive treatment of migraine in adults.
References: 1. Parsabiv® (etelcalcetide) prescribing information, Amgen. 2. Data on file, Amgen; [Summary of Clinical Efficacy; 2015]. 3. Alexander ST, et al. Mol Pharmacol. 2015;88:853-865. 4. Data on file, Amgen; [Report R20130052, 2014]. 5. Chen P, et al. CPT Pharmacometrics Syst Pharmacol. 2016;5:484-494. 6. Sensipar® (cinacalcet) prescribing information, Amgen. 7. Ma JN, et al. J Pharmacol Exp Ther. 2011;337:275-284.